Overview

Effect of Statin Therapy on C-Reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)

Status:
Unknown status
Trial end date:
2009-12-01
Target enrollment:
0
Participant gender:
All
Summary
Hypothesis for this pilot study is that simvastatin will lower the levels of CRP and ET-1 in COPD patients.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
VA Loma Linda Health Care System
Treatments:
Simvastatin
Criteria
Inclusion Criteria:

- Medically optimized COPD patients

- Age 40-79 years.

- serum CRP levels >3mg/l

Exclusion Criteria:

- Current smoker

- COPD exacerbation in the last 2 months.

- Active hepatic or severe renal dysfunction.

- connective tissue disease, chronic inflammatory disease, malignancy, any acute
illness, leukocytosis (>10,000 white blood cells) or thrombocytosis (>450,000
platelets).

- Recent h/o myocardial infarction, angina in the last 6 months.

- Pregnancy.